Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Not yet. Current Alzheimer’s medications like lecanemab and donanemab have shown promise, but only for people in the early stages of the disease—and even then, they slow cognitive decline by just 27-35%. For the millions living with moderate to severe Alzheimer’s, there are no disease-modifying drugs approved by the FDA. A Cochrane systematic review analyzing 20,000 participants across 17 randomized trials found that anti-amyloid monoclonal antibodies “probably result in little to no difference in cognitive function or dementia severity” when used in broader patient populations beyond the earliest stages. In other words, if you’re hoping these newer drugs will help someone who’s already in the middle or advanced stages of the disease, today’s approved medications won’t deliver that benefit.
That doesn’t mean hope is lost, though. Pharmaceutical companies and research institutions are actively working to change this reality. There are currently 25 Phase 3 clinical trials testing treatments specifically for moderate-stage Alzheimer’s disease and another 9 Phase 3 trials for severe-stage disease. The pipeline has grown substantially, with a 35% increase in drug candidates and 40% more clinical trials compared to a decade ago. But between today’s limited options and tomorrow’s potential treatments lies an important gap that families need to understand.
Table of Contents
- What Do Current Alzheimer’s Drugs Actually Do?
- The Critical Treatment Gap for Moderate and Advanced Disease
- What’s in the Pipeline for Later Stages?
- Understanding Clinical Trial Participation as a Real Option
- The Reality of Drug Development Timelines and Safety Concerns
- What Families Can Do Now While Waiting for Progress
- The Future Outlook for Advanced Alzheimer’s Treatment
- Conclusion
What Current Alzheimer’s Drugs Actually Do Beyond Early Stages
The medications available today—lecanemab (Leqembi) and donanemab (Kisunla)—work by targeting amyloid, a protein that accumulates in the Alzheimer’s brain. When given to people in the early stages of cognitive decline, these drugs have demonstrated the ability to slow the rate of cognitive decline by 27-35% compared to placebo. This sounds meaningful, but the real-world impact is modest. A person taking these drugs might delay certain symptoms by several months, but the progression continues. The drugs are infusions that require regular clinic visits and regular monitoring through MRI brain scans, which adds logistical burden and medical costs.
These early-stage benefits come with risks that families rarely hear about until they’re already committed to treatment. Anti-amyloid monoclonal antibodies increase the risk of amyloid-related imaging abnormalities (ARIA)—essentially brain microhemorrhages or small infarcts—at a rate 4.35 times higher than in patients receiving placebo. While serious side effects remain uncommon in absolute terms, they do occur, and they require close monitoring. Some patients experience cognitive worsening, memory problems, or symptoms resembling stroke. Stopping the medication doesn’t always reverse these effects quickly.
The Critical Treatment Gap for Moderate and Advanced Disease
Here’s where the hope-to-reality gap becomes painfully clear: if someone is already in moderate or advanced Alzheimer’s disease, none of the currently approved medications will slow their cognitive decline. The disease has progressed beyond the biological stage where anti-amyloid therapy appears to work. Some researchers hypothesize that amyloid accumulation happens early in the disease process, and by the time someone is moderately or severely impaired, other mechanisms—including tau tangles, neuroinflammation, and neurodegeneration—have become the dominant drivers of decline. Targeting amyloid at that late stage is like trying to prevent a fire that’s already burned down to the foundation.
This gap is not theoretical. Families dealing with a loved one in moderate or advanced Alzheimer’s today have essentially no disease-modifying treatment options. They manage symptoms, support independence as much as possible, and focus on quality of life and comfort. The frustration is understandable: new drugs exist, they’re getting FDA approvals, and yet they don’t apply to the person you’re caring for. This is why understanding the stage of disease is so critical when making treatment decisions.
What’s in the Pipeline for Later Stages?
The clinical trial landscape suggests the field recognizes this gap and is trying to address it. The TRONTIER 1 and TRONTIER 2 Phase 3 trials, which began enrolling in late 2025, represent one of the most significant ongoing efforts. Each trial is enrolling approximately 800 participants with moderate Alzheimer’s disease to test newer therapeutic approaches. These trials reflect a strategic shift: researchers are explicitly studying whether newer drugs or drug combinations can help people further along in the disease trajectory. The results won’t be available for several more years, but they represent concrete evidence of research momentum.
Beyond these major trials, the broader pipeline shows meaningful growth. There are 25 Phase 3 trials currently evaluating treatments for moderate-stage Alzheimer’s and 9 Phase 3 trials for severe-stage disease. Many of these drugs are targeting mechanisms beyond just amyloid—including tau, neuroinflammation, and neuronal protection. The diversity of approaches is encouraging because it increases the chances that at least some of them will show efficacy where amyloid-focused drugs have not. However, it’s important to manage expectations: trial results don’t guarantee approval, and even approved treatments take time to reach clinical practice.
Understanding Clinical Trial Participation as a Real Option
For families with a loved one in moderate or advanced stages, participating in a clinical trial might be the only access to potentially beneficial new treatments today. Trials like TRONTIER are actively recruiting, and participation offers a structure of medical monitoring that wouldn’t otherwise be available. Participants receive regular cognitive assessments, brain imaging, and physician oversight—all coordinated by the research team. If a drug shows promise in your loved one’s subgroup, you may have continued access even after the trial ends, depending on the trial design. The tradeoff, of course, is significant.
Trial participation requires travel to a participating center, often multiple times per month. It requires commitment to a study protocol that may include placebo assignments (meaning there’s a chance your loved one receives a placebo rather than the experimental drug). There’s also the emotional cost of uncertainty: you’re hoping an unproven treatment helps, knowing it might not. But for people in moderate or advanced stages with no other medical options, this calculus sometimes makes sense. Caregivers should discuss trial eligibility and logistics thoroughly with their neurology team and the trial site before committing.
The Reality of Drug Development Timelines and Safety Concerns
Even when clinical trials show promise, the path from Phase 3 success to FDA approval to routine clinical practice takes years. The 27-35% benefit from lecanemab took roughly a decade of research and multiple clinical trials to establish and get approved. Newer drugs targeting different mechanisms or later disease stages will follow similar timelines. A drug showing promise in 2026 might not reach patients until 2029 or 2030—and by then, patients and caregivers who participated in trials or hoped for that treatment may have experienced significant disease progression.
Safety concerns also deserve emphasis. The higher rate of ARIA with anti-amyloid drugs highlights a fundamental reality: treating advanced Alzheimer’s is biologically complex. Brain-targeting drugs come with risks of serious side effects. As researchers develop new medications, they’ll need to balance efficacy against safety in populations whose brains are already significantly damaged. This may limit which drugs ultimately prove acceptable for use in moderate and advanced disease.
What Families Can Do Now While Waiting for Progress
If you’re caring for someone in moderate or advanced Alzheimer’s, several evidence-based approaches remain valuable even without disease-modifying medications. Cognitive stimulation—engaging activities tailored to the person’s remaining abilities—has shown benefits for quality of life and engagement. Physical exercise, particularly aerobic activity, may slow cognitive decline and support overall health. Social engagement and meaningful activities reduce behavioral symptoms and improve mood.
These interventions won’t stop Alzheimer’s progression, but they matter for wellbeing during the time available. Discussing clinical trial opportunities with your neurologist is also worthwhile. Trial sites can assess whether your loved one meets eligibility criteria for ongoing Phase 3 studies. The Alzheimer’s Association maintains a trial finder on its website where you can search for active studies in your region.
The Future Outlook for Advanced Alzheimer’s Treatment
The pharmaceutical pipeline growth—35% increase in drug candidates and 40% more clinical trials compared to a decade ago—suggests that the next five to ten years may bring meaningful advances. Researchers are pursuing multi-targeted approaches that address both amyloid and tau, as well as neuroinflammatory pathways. Some experimental drugs show promise in animal models of advanced disease, though translating that promise to humans remains uncertain.
The honest assessment is that we’re in a transition period. Today’s early-stage treatments offer modest benefits to a limited population. Tomorrow’s treatments, based on current research momentum, may eventually extend benefits to moderate and advanced stages—but that tomorrow isn’t today. Families need to make decisions in the present, with today’s options and evidence.
Conclusion
New Alzheimer’s medications represent genuine progress for early-stage disease, but they don’t help people in moderate or advanced stages. That’s a critical limitation to understand when considering treatment options or managing expectations. The good news is that the field is actively working to close this gap, with substantial clinical trial activity focused specifically on later-stage disease.
Results from these trials may reshape treatment possibilities over the coming years. In the meantime, the most practical approach is to have honest conversations with your neurologist about whether early-stage treatments apply to your situation, to stay informed about clinical trials in your region, and to remember that disease-modifying drugs are only one part of good dementia care. Cognitive stimulation, physical activity, social engagement, and supportive care remain valuable regardless of what new medications may or may not be available.
You Might Also Like
- Could NeuroEPO Become a New Alzheimer’s Treatment?
- Could Alzheimer’s Walks Help Families Feel Less Alone?
- Why New Alzheimer’s Treatments Need Careful Study
Related reading
- why Alzheimer’s Research Is Becoming More Personalized
- could Precision Medicine Change Dementia Care
- what Middle-Aged Adults Should Know About Dementia Warning Signs
- can Small Behavior Changes Signal Alzheimer’s Earlier Than Expected
- why Midlife Brain Health Matters More Than People Think
For more on this topic, see Alzheimer’s Association — medical tests.
